Product Name
DUX4, Blocking Peptide
Full Product Name
DUX4 Peptide - middle region
Product Gene Name
DUX4 blocking peptide
[Similar Products]
DUX4 peptide (MBS3235166) is used for blocking the activity of DUX4 antibody (MBS3210210)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence
Synthetic peptide located within the following region: ESRPWPGRRG PPEGRRKRTA VTGSQTALLL RAFEKDRFPG IAAREELARE
3D Structure
ModBase 3D Structure for Q9UBX2
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of DUX4 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DUX4 blocking peptide
This is a synthetic peptide designed for use in combination with anti-DUX4 Antibody, made
Target Description: DUX4 is involved in transcriptional regulation.
Product Categories/Family for DUX4 blocking peptide
Peptide
Applications Tested/Suitable for DUX4 blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for DUX4. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001264985
[Other Products]
NCBI GenBank Nucleotide #
NM_001278056.1
[Other Products]
UniProt Primary Accession #
Q9UBX2
[Other Products]
UniProt Protein Name
Double homeobox protein 4
UniProt Synonym Protein Names
Double homeobox protein 10
Protein Family
Double homeobox protein
UniProt Gene Name
DUX4??[Similar Products]
UniProt Entry Name
DUX4_HUMAN
UniProt Comments for DUX4
DUX4: May be involved in transcriptional regulation. Defects in DUX4 may be the cause of facioscapulohumeral muscular dystrophy (FSHD). FSHD is characterized by weakness of the muscles of the face, upper-arm and shoulder girdle. Severity is highly variable. Weakness is slowly progressive and about 20% of affected individuals eventually require a wheelchair. Approximately 70-90% of individuals have inherited the disease-causing deletion from a parent, and approximately 10-30% of affected individuals have FSHD as the result of a de novo deletion. Offsprings of an affected individual have a 50% chance of inheriting the deletion. Belongs to the paired homeobox family.
Protein type: DNA-binding
Chromosomal Location of Human Ortholog: 4q35
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
